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LETTER TO THE EDITOR
Management of COVID-19 in hemodialysis
patients: The Genoa experience
BACKGROUND
The current Coronavirus Disease-19 (COVID-19) pan-
demic represents a global challenge for citizens, health
systems, local, and national governments. Since no previ-
ous experience has prepared the scientific and medical
community to face such as widespread and rapid clinical
emergency, local experiences can be of help in defining
management strategies.1
In this commentary, we briefly report the approach to
the management of COVID-19 in hemodialysis patients
(HD), that we implemented at our Nephrology and Dial-
ysis Unit, located in Genoa, Italy—Clinica Nefrologica
Dialisi e Trapianto, Ospedale Policlinico San Martino-
Italy).
GENERAL CONSIDERATIONS
COVID-19 is caused by infection of severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2). It is charac-
terized by a variable clinical picture ranging from mild
symptoms to severe pneumonia and multiorgan failure.2
COVID-19 may involve adult patients of all ages, but it
appears particularly severe in older subjects with pre-
existent health problems.3
At the beginning of the outbreak in Italy, COVID-19
was suspected when clinical and epidemiological
(i.e., people from more active areas and/or direct contact
with COVID positive subjects) criteria coexisted.4 Then,
due to the spread of the disease, epidemiological criteria
were excluded and now clinical criteria are considered
sufficient for suspect COVID-19.
Current clinical criteria for COVID-19 suspicion
include fever, cough, dyspnea, myalgia, and fatigue
(while less commonly other signs, like diarrhea, anosmia,
and syncope have been reported).5 In the clinical prac-
tice, diagnosis of COVID-19 is mostly made by a reverse
transcription-polymerase chain reaction from nasopha-
ryngeal swabs, while more invasive technique, such as
the collection of bronchoalveolar lavage samples, have
reserved to intensive care setting. However, as comple-
mental tests, also because of the possibility of false-
negative results, serological tests are being developed and
validated.6
CONSIDERATIONS FOR HD PATIENTS
Renal patients appear at high risk for COVID-19 and
related complications because most of them are old, pre-
sent multiple comorbidities, and some of them may use
immunosuppressive drugs (for treatment of immune dis-
eases, transplantation, etc.).7
Maintenance HD patients present additional risk fac-
tors, that include chronic immune dysfunction, need to
go to the hospital for HD and undergo dialysis in shared
rooms (so increasing the risk of contact with infected
people).8 Each dialysis unit should implement local strat-
egies to early recognized patients affected by COVID-19,
providing better available care, and prevent disease diffu-
sion among the other patients and health staff. The indi-
vidual approach should be defined according to local
resources (including the availability of personal protective
equipment (PPE)).9
Dialysis patients should be instructed to stay at home
while off dialysis. All the patients and medical staff
should be advised to inform of fever or respiratory symp-
toms before arrival at the Dialysis Center by phone, while
patients should avoid public transport to reach Dialysis
Center.
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In our Nephrology and Dialysis Unit, 260 maintenance
HD patients are followed in two dialysis facilities, which
have the same configuration, but different locations (the
larger Unit is inside the main hospital building, while the
smaller Unit is in an isolated building). The main Unit
has 10 rooms with the possibility to have three addi-
tional isolated rooms, that currently have used as
(a) clean room, (b) COVID-19 positive room (for
suspected or confirmed patients, to be dialyzed sepa-
rately), and (c) room dedicated to collect nasopharyngeal
swabs. In other rooms, a minimal distance of 2 m
between dialysis stations is warranted. All the rooms are
sanitized after each use.
Briefly, at arrival in each Dialysis Unit, the patients
wait in a communal area in sits separated by at least
1.5 m. Then, each patient individually undergoes a
predialysis triage, consisting in the assessment of body
temperature, individuation of symptoms or signs sugges-
tive for COVID-19 (such as fever, cough, myalgia, diar-
rhea, and anosmia) and handwashing.
Suspected patients are moved to a dedicated room,
where they undergo a clinical evaluation, inclusive of
weighting, oxygen saturation measurement, arterial blood
gas test (also to evaluate potassium level) and nasopha-
ryngeal swab collection, by a physician provided with
appropriate PEE. According to this comprehensive evalu-
ation, the physician may decide to (a) send the patient to
the emergency department to perform further evalua-
tions; (b) send the patient back to home, postponing HD
session till the availability of nasopharyngeal swab result;
and (c) if it is not possible to delay the dialysis
(e.g., because of hyperkalemia or excessive weight gain),
to perform HD session in a separated room in the main
dialysis unit, considering the patient as suspected for
COVID-19, using dedicated dialysis machine and
appropriate PPE.
After the dialysis, if clinically stable, with an oxygen
saturation ≥ 96%, the suspected patient is considered
suitable for outpatient care and sent back home, other-
wise, he is sent to the Emergency Department for further
evaluation. For scheduling the next HD session, we wait
for the result of the nasopharyngeal swab. This manage-
ment is eased by the fact that our laboratory provides the
results of nasopharyngeal swabs mostly within 24 h.
If nasopharyngeal swab results positive for SARS-
COV-2 infection, after the disease notification, the
patient is dialyzed in a separated room, till the recovery
(defined as two consecutive negative nasopharyngeal
swabs).
Independently of COVID-19 status, at the end of dial-
ysis, all the patients leave the Dialysis Center one at time.
However, for both suspected and confirmed COVID-19
patients, it is mandatory to avoid public transport and
organize specific transport with appropriate PPE, sched-
uling a complete sanitization of the vehicles. The whole
procedure (triage, clinical evaluation, isolation of
suspected cases) is repeated for each patient before each
dialysis session. So, some patients may have multiple
nasopharyngeal swabs, if clinical suspect persists, also
considering the possibility of false-negative results. A
similar approach has been established for patients
reporting clinical symptoms while at home. In this case,
we take advantage of territorial services that can perform
house nasopharyngeal swab, while clinical evaluation is
performed by telephone monitoring.
Finally, in COVID-19 positive patients, a nasopharyn-
geal swab is repeated 14 days after the diagnosis and
then weekly, till recovery. Possible therapeutic
approaches are discussed with infectious disease consul-
tant. For specific procedures and preventive measures
(handwashing, nasopharynx swab, use of PPE, etc.) we
follow the World Health Organization (WHO) and Euro-
pean Renal Association-European Dialysis and Transplant
Association (ERA-EDTA) recommendations.10,11 In the
following flowcharts (Figures 1 and 2, respectively), we
reassume our current approach to COVID management
in HD patients, taking into account two possible scenar-
ios (i.e., suspected/confirmed COVID patients in dialysis
facility and at home).
GENOA EXPERIENCE: FIRST RESULTS
On 16 April, 30 out of the 122 nasopharyngeal swabs
collected resulted positive (24.5%), accounting for
17 patients (i.e., 6.5% of the total 260 patients) with a
confirmed COVID-19 diagnosis. Among them, four
patients (23%) were identified at home and 13 (77%)
before the dialysis. In 14 of them (82%) was possible to
postpone the dialysis till the availability of nasopharynx
swab result. Notably, among the confirmed COVID-19
cases, three patients (17%) presented an initial negative
nasopharynx swab, while they resulted positive to suc-
cessive controls. In addition, based on telephone and
hospital triage, other 22 patients (8.4% of the total num-
ber of patients) were suspected for COVID-19, mainly
because of fever. In 16 of them, dialysis treatment was
delayed, but nasopharynx swabs resulted negative, while
clinical symptomatology resolved or other causes were
found. Regarding clinical management, 6 out of the
17 confirmed patients (35%) needed hospitalization, of
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Figure 1 Management of COVID-19 in patients accessing to hemodialysis at Genoa Dialysis Unit. Sp02, oxygen saturation;
HD, hemodialysis; PPE, personal protective equipment.Patients and medical staff should wear a surgical mask all the time
and wash hands frequently. [Color figure can be viewed at wileyonlinelibrary.com]
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Figure 2 Management of COVID-19 in hemodialysis patients reporting symptoms while at home. Sp02, oxygen saturation;
HD, hemodialysis; PPE, personal protective equipment. [Color figure can be viewed at wileyonlinelibrary.com]
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whom 1 was admitted to ICU, while 11 (65%) were
managed as outpatients.
Overall, six patients (35%)—five hospitalized and one
outpatient—died after a mean of 8 days from diagnosis,
two patients recovered after a mean of 15 days from the
diagnosis, while nine patients currently remain on isola-
tion. Interestingly, at this time, the infection rate is
higher in the main dialysis Unit (14/160 patients, 8.7%)
when compared with the smaller one (3/80 patients,
3.7%), probably as a consequence of the higher number
of patients and dialysis unit location.
CONCLUSIONS
COVID-19 pandemic is still evolving so that it is conceiv-
able that our way to face this situation will change over
time. Many areas of uncertainness remain in the general
population, such as in HD patients. For example, (a) the
adequate duration and modality of isolation precautions
for COVID-19 positive patients, (b) the suitability to
cohort more than one patient with suspected or con-
firmed COVID-19, (c) the influence of structural and
spatial organization of Dialysis Units on infection spread
and control, and (d) the potential effects of immunomod-
ulatory and antiviral drugs in HD patients. In any case,
an ideal approach to manage COVID-19 in dialysis
patients does not exist and the flexibility of the manage-
ment strategies is crucial at this moment. Organizational
and clinical choices should be guided by local epidemiol-
ogy of the disease, local (human and equipment)
resources and growing knowledge on the physiopathol-
ogy of COVID-19 and its treatment.
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